ASH Interviews on CML by PatientPower now available
The following video interviews done by our partner Andrew Schorr of PatientPower have just been published and are available as webstreams:
- A CML Advocate's Perspective on News from ASH 2012: Interview with Greg Stephens, National CML Society
- The latest in CML: a Global Patient Advocate's Perspective with Jan Geissler, CML Advocates Network
- An Expert’s Perspective on Changing CML Treatment Options: Dr. Moshe Talpaz discusses whether or not the "big guns"of treatment should be used up front or saved as a later option
- Ponatinib Study Brings Positive Results For the Most Resistant Types of CML, Dr. Jorge Cortes
Video on Adherence in CML now available in English and Italian, plus versions with subtitles in German, Spanish, Hebrew, Dutch and Chinese
Taking medication exactly as prescribed is not always easy for many patients with chronic myeloid leukaemia. However, adherence, or taking the medication as prescribed by the doctor, is important, as it has a strong impact on the effectiveness of treatment. "Chronic Myeloid Leukemia: What you need to know about adherence to therapy" is a video that educates patients with CML about the importance of adherence to treatment. The video was developed by a European workgroup of 8 patient advocacy groups and CML experts, supported with in-kind resources from Bristol-Myers Squibb.
It is now available in English and Italian, and now also in versions with German, Hebrew, Dutch, Spanish and Chinese subtitles.
CML Horizons 2013: Registration has now started
We are looking forward to our 2nd CML Horizons conference held at the Hilton Prague Old Town, Prague, on 3-5 May 2013. The CML Steering Committee has worked hard to ensure that the conference includes topics of importance to the CML patient community and provides a unique opportunity for participants to share experiences and best practice. The conference will again feature a good mix of medical sessions with world-renowned CML experts like Tim Hughes from Australia, Gianantonio Rosti from Italy, Dina Ben Yehuda from Israel, Katerina Machova from the Czech Republic and Fabio Efficace from Italy, as well as sessions with advocacy topics e.g. on substandard drugs and generics, e-advocacy and social media, advocating to policy makers or how to run patient meetings.
Leaders of leukemia patient advocacy organisations are eligible to participate in this conference. More information can be found at http://www.cmladvocates.net/cmlhorizons2013
Now also in Chinese: Patient-friendly summary of ELN recommendations on CML management in 11 languages
While treatment guidelines are recognised as being the standard of care by haematologists, they can be difficult to understand by patients. To improve the information available to patients, an international CML workgroup of patient organisations and experts have developed a patient-friendly summary of the European LeukemiaNet's recommendations for CML management. Thanks to a great community effort, the summary is now available in Chinese (new!), English, French, Spanish, German, Italian, Macedonian, Polish, Serbian, Hungarian and Hebrew! The summary aims to help patients to better understand CML management and communicate with their doctors regarding treatment and diagnostics. The original recommendations for physicians were published by CML experts on behalf of the European LeukemiaNet (ELN) in the Journal of Clinical Oncology in 2009. Find the summaries in all languages at http://cmladvocates.net/cmlsummary.
Thanks to Shanghai Roots & Shoots, CML Home of Hope for providing the Chinese translation!
News on CML from the 2012 ASH Conference – our Patients' Perspective
|
At the 54th annual conference of the American Society for Hematology (ASH 2012), 159 results from clinical studies on CML were presented: 36 were presented orally, and 123 were featured on posters. We have personally chosen a selection of these in order to summarize the most important news e.g. updated data and new drugs in CML therapy, a new milestone to achieve <10% BCR-ABL at 3 months, "deep molecular remission" as a pre-requisite for a possible cessation of therapy, and Interferon combination studies. (English, German and Hebrew versions by Giora & Jan, Russian translation by Sodeystvie, Chinese translation by Shanghai Roots & Shoots, Serbian translation by CML Serbia, Arabic translation donated by Nicola Srouji - thank you!) |
Translations: |
1 comments
Results of our pilot survey on adherence just published in "Journal of Patient Compliance" (Vol 2 Issue 4)
The "Journal of Patient Compliance" (Vol 2 Issue 4) has just published our scientific article on the patient-driven pilot survey on adherence in CML:
Optimal
adherence to oral cancer therapy is of key importance to maximise treatment effectiveness in patients. With the advance of molecular target therapies, cancer treatment in more and more indications is transforming from in-hospital care towards oral treatment in an outpatient setting. With cancer becoming a chronic disease, patients are often required to take the drug indefinitely on a daily basis. Ensuring an optimal adherence to treatment over the long-term period could be a challenge. As data on the driving factors of nonadherence in oncology is scarce, a pan-European workgroup of the CML Advocates Network has conducted a pilot study which has unveiled differences of non-adherence between countries, administration types and use of adherence tools in Chronic Myeloid Leukemia. This pilot study has provided the groundwork for a larger global adherence study that is currently ongoing in 12 languages.
